Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesIdentification of macrophage migration inhibitory factor and human neutrophil peptides 1–3 as potential biomarkers for gastric cancer
British Journal of Cancer, 06/26/09
Mohri Y et al. - In a study to discover biomarkers for gastric cancer using a range of proteomic analyses of serum and tissue from gastric cancer pts and controls, it was found that proteomic analyses of serum and tissue indicate that human neutrophil peptides 1–3 (HNPs 1–3) and migration inhibitory factor (MIF) have potential as biomarkers for gastric cancer. In particular MIF may be useful, either alone or in combination with other markers, for diagnosing and monitoring gastric cancer.
Methods- Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer pts and 29 pts with benign gastric diseases.
- Expression differences were confirmed by enzyme-linked immunosorbent assay.
- Tissue analysis shows HNPs 1–3 elevated 10-fold in gastric cancer relative to adjacent normal mucosa.
- Macrophage MIF was increased 5-fold in the serum of gastric cancer pts relative to individuals with benign gastric disease.
- The large increase in MIF concentration in serum gives an area under the receiver operating characteristic curve of 0.85.
Today in GI Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Sponsor
Article Search
Sponsor
Sponsor